Kura Oncology to Report Third Quarter 2016 Financial Results
31 oct. 2016 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in the 9th European Scientific Oncology Conference
31 oct. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 9th European...
Kura Oncology to Participate in the 2016 Aegis Growth Conference
14 sept. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Aegis Growth...
Kura Oncology to Participate in the 5th Annual Gateway Conference
02 sept. 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 Gateway...
Kura Oncology Reports Second Quarter 2016 Financial Results
10 août 2016 16h03 HE
|
Kura Oncology, Inc.
Promising clinical activity observed in Phase 2 trial of tipifarnib in HRAS mutant solid tumors has triggered additional patient enrollment Management to host webcast and conference call today at...
Kura Oncology to Report Second Quarter 2016 Financial Results
03 août 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced it will report second quarter 2016 financial...
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes
16 juin 2016 17h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced the first patient has been dosed in a Phase 2...
Kura Oncology to Participate in the 2016 JMP Life Sciences Conference
14 juin 2016 07h30 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced its participation in the 2016 JMP Life Sciences...
Kura Oncology Reports First Quarter 2016 Financial Results
11 mai 2016 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company, today reported financial results for the first quarter ended March...
Kura Oncology Reports Fourth Quarter and Full Year 2015 Operational and Financial Results
17 mars 2016 16h05 HE
|
Kura Oncology, Inc.
LA JOLLA, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company, today announced highlights and financial results for the fourth...